Undervalued Biotechnology Stocks on NAS September 2023

September 23, 2023

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
ZLAB Zai Lab 23.98 52.30 118.10 498529 2314 0.00 0.0
MRNA Moderna 100.23 194.26 93.82 3763859 38188 0.00 34.8
CRSP CRISPR Therapeutics 46.06 82.60 79.33 803662 3643 0.00 0.0
DNLI Denali Therapeutics 22.50 34.20 52.02 733202 3171 0.00 0.0
RPRX Royalty Pharma 26.26 38.81 47.79 2479365 15910 3.01 47.7
BNTX BioNTech 106.43 156.92 47.44 566035 25651 0.00 5.5
MLTX MoonLake 53.19 75.00 41.00 545542 2325 0.00 0.0
INCY Incyte 58.79 82.50 40.33 1804026 13266 0.00 36.1
HRMY Harmony Biosciences 35.72 47.05 31.73 662399 2170 0.00 10.9
GMAB Genmab 36.49 46.33 26.98 402303 24026 0.00 35.4
All data provided as at market close September 20, 2023.

Company Details

Zai Lab

ZLAB:NAS

Close Price

23.98

Our Valuation

52.30

% Difference

118.10

Market Cap ($M)

2314

P/E Ratio

0.0

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases.

Access the stockcalc valuation


Moderna

MRNA:NAS

Close Price

100.23

Our Valuation

194.26

% Difference

93.82

Market Cap ($M)

38188

P/E Ratio

34.8

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Access the stockcalc valuation


CRISPR Therapeutics

CRSP:NAS

Close Price

46.06

Our Valuation

82.60

% Difference

79.33

Market Cap ($M)

3643

P/E Ratio

0.0

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases.

Access the stockcalc valuation


Denali Therapeutics

DNLI:NAS

Close Price

22.50

Our Valuation

34.20

% Difference

52.02

Market Cap ($M)

3171

P/E Ratio

0.0

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Royalty Pharma

RPRX:NAS

Close Price

26.26

Our Valuation

38.81

% Difference

47.79

Market Cap ($M)

15910

P/E Ratio

47.7

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry.

Access the stockcalc valuation


BioNTech

BNTX:NAS

Close Price

106.43

Our Valuation

156.92

% Difference

47.44

Market Cap ($M)

25651

P/E Ratio

5.5

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators.

Access the stockcalc valuation


MoonLake

MLTX:NAS

Close Price

53.19

Our Valuation

75.00

% Difference

41.00

Market Cap ($M)

2325

P/E Ratio

0.0

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Access the stockcalc valuation


Incyte

INCY:NAS

Close Price

58.79

Our Valuation

82.50

% Difference

40.33

Market Cap ($M)

13266

P/E Ratio

36.1

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma).

Access the stockcalc valuation


Harmony Biosciences

HRMY:NAS

Close Price

35.72

Our Valuation

47.05

% Difference

31.73

Market Cap ($M)

2170

P/E Ratio

10.9

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Access the stockcalc valuation


Genmab

GMAB:NAS

Close Price

36.49

Our Valuation

46.33

% Difference

26.98

Market Cap ($M)

24026

P/E Ratio

35.4

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Zai Lab and Moderna are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-september-2023
Zai Lab $ZLAB and Moderna $MRNA are the most undervalued Biotechnology stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-september-2023
Zai Lab and Moderna are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-september-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.